))
Anticoagulants may improve outcomes for hospitalized patients
アーカイブされたシリーズ ("無効なフィード" status)
When?
This feed was archived on August 02, 2022 01:33 (
Why? 無効なフィード status. サーバーは持続期間に有効なポッドキャストのフィードを取得することができませんでした。
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 286024793 series 2880701
コンテンツは Pharmaceutical Bank によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Pharmaceutical Bank またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作権で保護された作品をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Hello,
Depending on the interim results of over 1,000 moderately ill patients admitted to hospital, findings demonstrated that complete doses of blood thinners, along with being secure, were superior to the dosages generally given to prevent blood clots in elderly patients--with respect to the primary endpoint that's the demand for venting or other manhood supportive interventions. The trial researchers are currently working as quickly as you can create the entire results of the research accessible so clinicians can make informed decisions regarding treating their COVID-19 patients. Three clinical trial programs spanning five continents in over 300 hospitals are working together to test whether there's a higher advantage of complete doses of heparin (blood thinners) to deal with moderately ill hospitalized adults using COVID-19 when compared with lower heparin dose generally administered to stop blood clots in elderly patients. Moderately sick patients are not in intensive care and didn't receive manhood assistance including mechanical ventilation in trial registration.
Visit our podcasts page for more podcasts and tips related to the pharmaceutical industry.
5 つのエピソード
シェア
